CTI BioPharma (CTIC) has risen sharply, recording gains of 4.48% in the past 4 weeks. However, the stock has corrected -0.03% in the past 1 week, providing a good buying opportunity on dips. CTI BioPharma (CTIC) : Traders are bullish on CTI BioPharma (CTIC) as it has outperformed the S&P 500 by a wide margin of 4.7% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.63%, relative to the S&P 500.
Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 0.04% and the fifty day Moving Average is 2.2%. CTI BioPharma Corp. has dropped 23.65% during the last three month period . Year-to-Date the stock performance stands at -71.54%.
CTI BioPharma (CTIC) : The highest level CTI BioPharma (CTIC) is projected to reach is $5 for the short term and the lowest estimate is at $1. The consolidated price target from 2 rating analysts who initiate coverage on the stock is $2.88 and the possibility the share price can swing is $3.01.
CTI BioPharma (NASDAQ:CTIC): stock turned positive on Friday. Though the stock opened at $0.344, the bulls momentum made the stock top out at $0.3532 level for the day. The stock recorded a low of $0.344 and closed the trading day at $0.35, in the green by 1.45%. The total traded volume for the day was 347,697. The stock had closed at $0.345 in the previous days trading.
CTI BioPharma Corp. (CTI), formerly Cell Therapeutics, Inc., is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is focused on commercializing PIXUVRI (pixantrone), or PIXUVRI, in the European Union, for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL), and conducting a Phase III clinical trial program of pacritinib for the treatment of adult patients with myelofibrosis to support regulatory submission for approval in the United States and Europe. It is also engaged in evaluating pacritinib in earlier clinical trials as treatment for other blood-related cancers. Its development product candidates include tosedostat and Opaxio.